Komori
Dividends4506Sumitomo Pharma Co.,Ltd.Pharmaceuticals

Notice Regarding Revision to the Year-End Dividend Forecast for the Fiscal Year Ending March 2027

The year-end dividend forecast for the fiscal year ending March 2027 has been set at ¥15 per share, up from undetermined. The interim dividend will remain at zero, but the annual dividend will be ¥15, restoring a dividend after none was paid in the previous fiscal year.

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
15
Yen per share
Wording
Definitive
How definitive the wording is.

Dividend per share

Fiscal year ending March 2027
15YenDividend per share for this transactionPrior-year result ¥0, change ¥+15
Previous-period resultsCurrent

Each vertical step represents one dividend payment, and the total height of the accumulated steps represents the annual dividend for the period. For periods showing only the annual amount, the payment breakdown is not provided, so only the end point is plotted.

Dividend policy

To be determined based on business trends and other factors, under a policy of prioritizing strengthening financial soundness and growth investment, particularly in research and development.

Dividend per share
ItemDetails
Dividend per shareNot disclosed → ¥15.00(Not calculable (the previous forecast was -))
Total Annual DividendsNot disclosed → ¥15.00(Not calculable (the previous forecast was -))
Previous-period results (per share)Interim ¥0.00 / End of period ¥0.00 / Annual ¥0.00
Dividend policyTo be determined based on business trends and other factors, under a policy of prioritizing strengthening financial soundness and growth investment, particularly in research and development.
Fiscal Period CoveredFiscal year ending March 2027
Items this document does not state (7)
Total dividendsRecord dateEffective dateSource of dividendsBreakdown of Regular, Commemorative and Special DividendsPayout ratioWhether Submission to the General Meeting of Shareholders Is Required

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To prioritize strengthening financial soundness and growth investment, particularly in research and development, while considering performance progress through the second quarter and the outlook ahead, and to resume returning profits to shareholders.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Revision to the Year-End Dividend Forecast for the Fiscal Year Ending March 2027 | Sumitomo Pharma Co.,Ltd. (4506) timely disclosure | Komori